All three studies used dosage-escalation schemes in their protocols, allowing for haloperidol and risperidone to reach steady-state levels faster than did iloperidone. The use of such a method may ...
Purpose. The pharmacology, pharmacokinetics, pharmacogenomics, clinical efficacy, and safety and tolerability profile of iloperidone for the treatment of schizophrenia are reviewed. Summary.
Titan Pharmaceuticals’ Phase III efficacy and safety trials demonstrate that iloperidone is associated with greater improvements in the symptoms of schizophrenia versus placebo.